Dr. Kersun has a strong interest in trainee education and collaborates with colleagues at Children's Hospital of Philadelphia and other institutions to develop innovative methods of teaching various topics in oncology. She also engages in collaborative research related to the communication of difficult news to patients.
Dr. Freedman has a particular interest in epidemiologic and translational research within pediatric supportive oncology. He aims to advance the understanding and treatment of symptoms, infections, and organ toxicities in pediatric cancer and hematopoietic stem cell transplant patients.
Dr. Adamson serves as chair of the international consortium Children's Oncology Group and on the National Cancer Advisory Board. In addition to his national and international leadership roles in pediatric oncology, Dr. Adamson maintains a dynamic research program on pediatric clinical-translational drug development, with a strong focus on childhood cancer drug development.
Dr. Rheingold's research interests center on acute lymphocytic leukemia, and she serves on the Children's Oncology Group's Relapsed ALL, Infant ALL, and Complementary Therapies committees. In addition, she is investigates complementary and alternative therapies, supportive care for oncology patients undergoing chemotherapy, medical education, and rare childhood tumors.
Dr. Seif's research centers on manipulating the human innate and immune systems to treat children with acute lymphoblastic leukemia (ALL). The long-term goal of her research is to identify innate and adaptive immune mechanisms that can be used to treat pediatric ALL more effectively, and with less toxicity, than existing therapies.
Dr. Hunger's focuses his research on molecular and genomic approaches to identify and clinically evaluate targeted cancer treatments for children with relapsed or high-risk acute lymphoblastic leukemia (ALL) such as Philadelphia chromosome-like (Ph-Like) ALL. The long-term goal of Dr. Hunger’s research is to develop better therapies, improve cure rates, and minimize treatment toxicities for children with ALL.
Dr. Phillips' research interests involve learning health systems and the intersection of technology and clinical informatics with clinical research for pediatric oncology patients. His current focus is on developing novel automated methods to identify cancer patients with malnutrition and optimizing their nutritional support. He has a secondary interest in quality improvement research for supportive care in pediatric oncology.
Dr. Mostoufi-Moab's clinical and research program is focused on endocrine late effects after childhood cancer therapy. She has unique dual training in pediatric endocrinology and oncology with a master's degree in clinical epidemiology. The goal of her research program is to pursue a mechanistic understanding of metabolic and endocrine disorders that occur due to cancer therapy.
Dr. Snyder is a pediatric hematologist oncologist focused on improving the lives of people living with vascular anomalies. She is involved with national and international endeavors to create educational programs and investigational registries, investigate treatments, and author publications in this discipline.